Inhibitors of NAMPT, such as FK866, reduce NAD+ levels, induce canonical apoptosis preferentially in cancer cells in vitro, inhibit tumor growth, and increase overall survival in preclinical cancer models.1, 5, 6, 7 FK866 (APO866) was relatively well tolerated in humans and advanced to phase II clinical trials. The gene discussed is NAMPT; the disease is cancer.